Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide black; macrogol 6000; colloidal anhydrous silica; lactose monohydrate; titanium dioxide; croscarmellose sodium; purified talc; microcrystalline cellulose; hyprolose; iron oxide red; magnesium stearate - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - hydrochlorothiazide,irbesartan -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lupin healthcare (uk - hydrochlorothiazide; irbesartan - tablet - 25mg ; 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - hydrochlorothiazide; irbesartan - tablet - 25mg ; 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - hydrochlorothiazide; irbesartan - tablet - 25mg ; 300mg

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type b; polysorbate 80; mannitol; hypromellose; magnesium stearate; povidone; titanium dioxide; iron oxide red; macrogol 3350; carnauba wax; iron oxide black - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide tablets may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide tablets as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal w

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

apotex europe b.v. - hydrochlorothiazide 25 mg; irbesartan 300 mg - film-coated tablet - 300 mg - 25 mg - hydrochlorothiazide 25 mg; irbesartan 300 mg - irbesartan and diuretics

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synerrv sdn bhd - irbesartan; hydrochlorothiazide -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet - excipient ingredients: colloidal anhydrous silica; hydrogenated castor oil; microcrystalline cellulose; maize starch; magnesium stearate; lactose monohydrate; croscarmellose sodium; povidone - stada irbesartan hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.